



Spruce Biosciences to Participate in May Investor Conferences

May 2, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 2, 2023-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May.

- **The JMP Securities Life Sciences Conference**

Date: May 15-16, 2023

Format: [Fireside chat](#) (May 15, 2023 at 1:30 p.m. ET) and 1x1 meetings

- **2023 RBC Capital Markets Global Healthcare Conference**

Date: May 16-17, 2023

Format: [Fireside chat](#) (May 17, 2023 at 3:05 p.m. ET) and 1x1 meetings

Interested parties can access the webcast for each conference presentation from the [Events](#) section of the company's investor relations website at <https://investors.sprucebiosciences.com>. A replay of the webcasts will be available after the conclusion of the live presentations for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @[Spruce_Bio](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20230502005399/en/>

Media Contact

Will Zasadny

Evoke Canale

(619) 961-8848

will.zasadny@evokecanale.com

media@sprucebio.com

Investors

Xuan Yang

Solebury Strategic Communications

(415) 971-9412

xyang@soleburystrat.com

investors@sprucebio.com

Source: Spruce Biosciences, Inc.